Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Athersys, Inc. ATHX
$0.82
+$0.02 (1.95%)
На 18:00, 12 мая 2023
+509.76%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
16776908.00000000
-
week52high
19.50
-
week52low
0.50
-
Revenue
5325000
-
P/E TTM
0
-
Beta
-0.70415200
-
EPS
-5.84000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:00
Описание компании
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| B of A Securities | Underperform | Neutral | 23 мая 2022 г. |
| B of A Securities | Neutral | Neutral | 16 мар 2022 г. |
| B of A Securities | Neutral | Buy | 19 ноя 2021 г. |
| B of A Securities | Buy | 25 июн 2020 г. | |
| Needham | Buy | Buy | 08 мая 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Kola Ismail | A | 60226 | 35714 | 09 янв 2023 г. |
| WYSZOMIERSKI JACK L | A | 35141 | 22321 | 09 янв 2023 г. |
| Wasman Jane | A | 35141 | 22321 | 09 янв 2023 г. |
| Nolan Joseph Patrick | A | 27428 | 27428 | 09 янв 2023 г. |
| Nolan Joseph Patrick | A | 21951 | 21951 | 09 янв 2023 г. |
| Hansen Maia | D | 91899 | 8253 | 04 янв 2023 г. |
| Camardo Daniel A. | D | 345320 | 23484 | 04 янв 2023 г. |
| Hansen Maia | D | 7559 | 67 | 19 дек 2022 г. |
| Camardo Daniel A. | A | 368804 | 100000 | 22 ноя 2022 г. |
| Camardo Daniel A. | A | 268804 | 263492 | 04 окт 2022 г. |
Новостная лента
Athersys to Host Business Update Conference Call on April 20th
Business Wire
10 апр 2023 г. в 15:29
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on April 20, 2023 at 11:00 a.m. Eastern Time.
Athersys to Host Business Update Conference Call on February 14th
Business Wire
02 февр 2023 г. в 08:30
CLEVELAND--( BUSINESS WIRE )--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on February 14, 2023 at 11:00 a.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Robert “Willie” Mays, Executive Vice President Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company's recent clinical and operational progress, upcoming milestones and vision for the year.
Athersys, Inc. (ATHX) Q3 2022 Earnings Call Transcript
Seeking Alpha
15 ноя 2022 г. в 16:19
Athersys, Inc. (NASDAQ:ATHX ) Q3 2022 Earnings Conference Call November 15, 2022 11:00 AM ET Company Participants Ellen Gurley – Corporate Communications and Investor Relations Dan Camardo – Chief Executive Officer Kasey Rosado – Interim Chief Financial Officer Conference Call Participants Operator Good morning. My name is Devon and I will be your conference operator today.
Athersys to Present at Challenges and Opportunities for Mesenchymal Stem Cells Digital Conference and Participate in A.G.P.'s Biotech Conference
Business Wire
11 ноя 2022 г. в 08:30
CLEVELAND--( BUSINESS WIRE )--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today its participation in two November conferences, the Challenges and Opportunities for Mesenchymal Stem Cells digital conference being held November 17-18, 2022 and A.G.P.'s Biotech Conference on November 30, 2022.
Athersys to Host Third Quarter Financial Results Call
Business Wire
25 окт 2022 г. в 08:30
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) will be hosting a conference call on Thursday, November 10, 2022, at 4:30 PM Eastern Time to review its third quarter 2022 financial results.